These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36524812)
41. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Baumann C; Ullrich A; Torka R Mol Oncol; 2017 Oct; 11(10):1430-1447. PubMed ID: 28675785 [TBL] [Abstract][Full Text] [Related]
42. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling. Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217 [TBL] [Abstract][Full Text] [Related]
43. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Miller MA; Oudin MJ; Sullivan RJ; Wang SJ; Meyer AS; Im H; Frederick DT; Tadros J; Griffith LG; Lee H; Weissleder R; Flaherty KT; Gertler FB; Lauffenburger DA Cancer Discov; 2016 Apr; 6(4):382-99. PubMed ID: 26984351 [TBL] [Abstract][Full Text] [Related]
44. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599 [TBL] [Abstract][Full Text] [Related]
45. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455 [TBL] [Abstract][Full Text] [Related]
46. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors. Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742 [TBL] [Abstract][Full Text] [Related]
47. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310 [TBL] [Abstract][Full Text] [Related]
48. Efficient Arylation of 2,7-Naphthyridin-1(2 Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005 [TBL] [Abstract][Full Text] [Related]
49. In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling. Peter SC; Mannu J; Mathur PP Methods Mol Biol; 2017; 1549():221-229. PubMed ID: 27975295 [TBL] [Abstract][Full Text] [Related]
50. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689 [TBL] [Abstract][Full Text] [Related]
51. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492 [TBL] [Abstract][Full Text] [Related]
52. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012 [TBL] [Abstract][Full Text] [Related]
53. AXL regulates mesothelioma proliferation and invasiveness. Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014 [TBL] [Abstract][Full Text] [Related]
54. Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation. Poświata A; Kozik K; Miączyńska M; Zdżalik-Bielecka D Cell Mol Life Sci; 2022 May; 79(6):316. PubMed ID: 35622156 [TBL] [Abstract][Full Text] [Related]
55. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347 [TBL] [Abstract][Full Text] [Related]
56. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860 [TBL] [Abstract][Full Text] [Related]
57. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors. Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239 [TBL] [Abstract][Full Text] [Related]
58. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis. Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH Cells; 2021 Oct; 10(11):. PubMed ID: 34831142 [TBL] [Abstract][Full Text] [Related]